Study details
Enrolling now
A Study to Evaluate Solriktug in Adult Participants With Asthma
Uniquity One (UNI)
NCT IDNCT06496607ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
124
Study length
about 1.8 years
Ages
18–75
Locations
74 sites in AL, AZ, CA +23
About this study
Researchers are testing solriktug, a biological treatment, in adult participants with asthma. The trial will evaluate the safety and tolerability of solriktug compared to placebo over 12 weeks. Participants will receive either solriktug or placebo via subcutaneous injection at it site.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive NSI-8226
- 2.Receive Placebo
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: To assess the safety and tolerability of multiple doses of solrikitug
Body systems
Respiratory